India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports
BUZZ-India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports Updates
** Nifty Pharma Index .NIPHARM down 1.52%
** Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS, Cipla CIPL.NS, Lupin LUPN.NS, Glenmark GLEN.NS, Dr Reddy's REDY.NS and Zydus ZYDU.NS decline 1.2%-3.9%, with Lupin the worst hit
** Trump says imported generic drugs will remain tariff-free for two years from August 1, before tariffs increase to 100% for one year and 200% thereafter
** "The headline is negative, but key details around implementation, legal challenges, exemptions and final scope remain unclear ... We would view it more as a policy signal than a quantifiable earnings event" - Niharika Agarwal, analyst at Nirmal Bang
** PL Capital says existing U.S. facilities may partly cushion impact, but two years is too short to relocate entire generic pharma value chain
** Motilal Oswal says tariff implementation remains uncertain, with major impact due from August 2028, near end of Trump's term
(Reporting by Abhinav Parmar in Bengaluru)
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter